Amgen terminated its collaboration with Kyowa Kirin on the anti‑OX40 antibody rocatinlimab, exiting a program for which it had previously paid $400 million in rights. Industry reports indicate Amgen’s decision follows an extended pivotal program and a reassessment of strategic priorities in autoimmune indications. The termination removes Amgen from late‑stage commitments on the candidate and returns program control to Kyowa Kirin, which may now re‑evaluate development options. The move highlights how large biologics developers continue to re‑balance portfolios in response to shifting clinical readouts and competitive landscapes in immunology.